Oseltamivir Phosphate for Oral Suspension

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
Oseltamivir Phosphate for Oral Suspension
Generic name
OSELTAMIVIR PHOSPHATE
Manufacturer
Oryza Pharmaceuticals Inc.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
11cf45d4-0e6c-4408-bbe6-5ed94468cf2e
SPL ID
4627bcf0-5295-1d6d-e063-6394a90ab3ce
Version
2
Effective date
2025-12-17
Source export date
2026-11-13
Source partition
6
Source file
https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:21:20
Harmonized routes table
Harmonized routes
ORAL

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 2 · 5 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Serious skin/hypersensitivity reactions such as Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme: Discontinue Oseltamivir Phosphate for Oral Suspension and initiate appropriate treatment if allergic-like reactions occur or are suspected. ( 5.1 ) Neuropsychiatric events: Patients with influenza, including those receiving Oseltamivir Phosphate for Oral Suspension , particularly pediatric patients, may be at an increased risk of confusion or abnormal behavior early in their illness. Monitor for signs of abnormal behavior. ( 5.2 ) 5.1 Serious Skin/Hypersensitivity Reactions Cases of anaphylaxis and serious skin reactions including toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme have been reported in postmarketing experience with Oseltamivir Phosphate for Oral Suspension. Stop Oseltamivir Phosphate for Oral Suspension and institute appropriate treatment if an allergic-like reaction occurs or is suspected. The use of Oseltamivir Phosphate for Oral Suspension is contraindicated in patients with known serious hypersensitivity to Oseltamivir Phosphate for Oral Suspension [see Contraindications ( 4 ) and Adverse Reactions ( 6.2 )] . 5.2 Neuropsychiatric Events There have been postmarketing reports of delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes, in patients with influenza who were receiving Oseltamivir Phosphate for Oral Suspension [see Adverse Reactions ( 6.2 )] . Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made but they appear to be uncommon based on Oseltamivir Phosphate for Oral Suspension usage data. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of Oseltamivir Phosphate for Oral Suspension to these events has not been established. Influenza can be associated with a variety of neurologic and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease. Closely monitor oseltamivir phosphate for oral suspension-treated patients with influenza for signs of abnormal behavior. If neuropsychiatric symptoms occur, evaluate the risks and benefits of continuing Oseltamivir Phosphate for Oral Suspension for each patient. 5.3 Risk of Bacterial Infections There is no evidence for efficacy of Oseltamivir Phosphate for Oral Suspension in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. Oseltamivir Phosphate for Oral Suspension has not been shown to prevent such complications. Prescribers should be alert to the potential for secondary bacterial infections and treat them as appropriate. 5.4 Fructose Intolerance in Patients with Hereditary Fructose Intolerance Fructose can be harmful to patients with hereditary fructose intolerance. One dose of 75 mg Oseltamivir Phosphate for Oral Suspension delivers 2 grams of sorbitol. This is above the daily maximum limit of sorbitol for patients with hereditary fructose intolerance and may cause dyspepsia and diarrhea.

warnings and cautions

5.1 Serious Skin/Hypersensitivity Reactions Cases of anaphylaxis and serious skin reactions including toxic epidermal necrolysis, Stevens-Johnson Syndrome, and erythema multiforme have been reported in postmarketing experience with Oseltamivir Phosphate for Oral Suspension. Stop Oseltamivir Phosphate for Oral Suspension and institute appropriate treatment if an allergic-like reaction occurs or is suspected. The use of Oseltamivir Phosphate for Oral Suspension is contraindicated in patients with known serious hypersensitivity to Oseltamivir Phosphate for Oral Suspension [see Contraindications ( 4 ) and Adverse Reactions ( 6.2 )] .

warnings and cautions

5.2 Neuropsychiatric Events There have been postmarketing reports of delirium and abnormal behavior leading to injury, and in some cases resulting in fatal outcomes, in patients with influenza who were receiving Oseltamivir Phosphate for Oral Suspension [see Adverse Reactions ( 6.2 )] . Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made but they appear to be uncommon based on Oseltamivir Phosphate for Oral Suspension usage data. These events were reported primarily among pediatric patients and often had an abrupt onset and rapid resolution. The contribution of Oseltamivir Phosphate for Oral Suspension to these events has not been established. Influenza can be associated with a variety of neurologic and behavioral symptoms that can include events such as hallucinations, delirium, and abnormal behavior, in some cases resulting in fatal outcomes. These events may occur in the setting of encephalitis or encephalopathy but can occur without obvious severe disease. Closely monitor oseltamivir phosphate for oral suspension-treated patients with influenza for signs of abnormal behavior. If neuropsychiatric symptoms occur, evaluate the risks and benefits of continuing Oseltamivir Phosphate for Oral Suspension for each patient.

warnings and cautions

5.3 Risk of Bacterial Infections There is no evidence for efficacy of Oseltamivir Phosphate for Oral Suspension in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza. Oseltamivir Phosphate for Oral Suspension has not been shown to prevent such complications. Prescribers should be alert to the potential for secondary bacterial infections and treat them as appropriate.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 2 of 2 · 5 matching rows.

adverse reactions table

<table width="90%"><caption>Table 5 Adverse Reactions Occurring in &#x2265;1% of Adults and Adolescents (13 years of age and older) in Treatment and Prophylaxis Trials*</caption><tfoot><tr styleCode="First Last"><td colspan="5" align="left">* Adverse reactions that occurred in &#x2265;1% of Oseltamivir Phosphate for Oral Suspension-treated adults and adolescents and &#x2265;1% greater in Oseltamivir Phosphate for Oral Suspension-treated subjects compared to placebo-treated subjects in either the treatment or prophylaxis trials.</td></tr></tfoot><tbody><tr><td rowspan="2" styleCode="Botrule"><content styleCode="bold"><content styleCode="italics">System Organ Class</content></content><content styleCode="bold"> Adverse Reaction </content></td><td colspan="2" align="center" styleCode="Botrule"><content styleCode="bold">Treatment Trials</content></td><td colspan="2" align="center" styleCode="Botrule"><content styleCode="bold">Prophylaxis Trials</content></td></tr><tr align="center"><td align="center" styleCode="Botrule"><paragraph><content styleCode="bold">Oseltamivir</content><content styleCode="bold">Phosphate</content><content styleCode="bold"> 75 mg twice daily </content></paragraph><paragraph><content styleCode="bold"/><content styleCode="bold">(n = 2,646)</content></paragraph></td><td styleCode="Botrule"><content styleCode="bold">Placebo</content><content styleCode="bold"> (n = 1,977) </content></td><td styleCode="Botrule"><paragraph><content styleCode="bold">Oseltamivir Phosphate</content></paragraph><paragraph><content styleCode="bold"/><content styleCode="bold"> 75 mg once daily</content> <content styleCode="bold">(n = 1,943)</content></paragraph></td><td styleCode="Botrule"><paragraph><content styleCode="bold">Placebo</content></paragraph><paragraph><content styleCode="bold"/><content styleCode="bold">(n = 1,586)</content></paragraph></td></tr><tr><td><content styleCode="italics">Gastrointestinal Disorders</content></td><td/><td/><td/></tr><tr align="center"><td align="left"> Nausea</td><td>10%</td><td>6%</td><td> 8%</td><td> 4%</td></tr><tr align="center" styleCode="Botrule"><td align="left"> Vomiting</td><td>8%</td><td>3%</td><td>2%</td><td>1%</td></tr><tr><td><content styleCode="italics">Nervous System Disorders</content></td><td/><td/><td/><td/></tr><tr align="center"><td align="left"> Headache</td><td>2% </td><td>1% </td><td> 17%</td><td>16%</td></tr><tr><td><content styleCode="italics">General Disorders </content></td><td/><td/><td/><td/></tr><tr align="center"><td align="left"> Pain</td><td>&lt;1%</td><td>&lt;1%</td><td> 4%</td><td> 3%</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.